Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Working Adults Clear all
Terminated Not applicable Interventional

Effect and Utilization of Protected Time Among Interns on Extended Duty-Hour Call Shifts

NCT00983008
View directory record Official record
Conditions
Fatigue, Sleep Deprivation, Depression
Interventions
Protected time and Dedicated time
Behavioral
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

NCT00054483
View directory record Official record
Conditions
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
bortezomib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Not applicable Interventional

Enhanced Discharge Planning Program -- Prospective

NCT01378234
View directory record Official record
Conditions
Patient Admission, Patient Discharge
Interventions
Enhanced Discharge Planning Program transitional care
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
65 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study To Investigate If Embody's Retinol Gummies Improve The Early Signs Of Skin Aging And Overall Skin Health

NCT04884516
View directory record Official record
Conditions
Acne, Adult
Interventions
Retinol gummy
Dietary Supplement
Lead sponsor
Embody Beauty, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 22, 2026, 1:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

NCT05125016
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
REGN4336, REGN5678
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Interventions
REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 1:48 AM EDT
Recruiting Phase 3 Interventional

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286
View directory record Official record
Conditions
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Interventions
Odronextamab, Lenalidomide, Rituximab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
8
States / cities
Los Angeles, California • Plantation, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Moderate-intensity Flow-based Yoga Effects on Cognition and Stress

NCT04740229
View directory record Official record
Conditions
Stress, Psychological
Interventions
Yoga
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Jul 22, 2026, 1:48 AM EDT
Recruiting Phase 3 Interventional

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nitrate and Exercise Performance in Middle to Older Aged Adults

NCT03371966
View directory record Official record
Conditions
Aging
Interventions
High Nitrate Beetroot Juice, Low Nitrate Beetroot Juice
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
40 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Phase 2Phase 3 Interventional

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

NCT05729373
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
SEP-363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
38
States / cities
Huntsville, Alabama • Phoenix, Arizona • Culver City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 22, 2026, 1:48 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

NCT05873751
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Meningococcal Vaccines
Interventions
Trumenba Vaccine, MenACWY Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Years to 30 Years
Enrollment
1,307,378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Jul 22, 2026, 1:48 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Effects of Youth Mental Health First Aid (YMHFA) on South Asian American Adults Working With South Asian American Youth

NCT07135479
View directory record Official record
Conditions
Waitlist Control, Experimental
Interventions
Youth Mental Health First Aid
Other
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

NCT05495581
View directory record Official record
Conditions
Healthy Volunteers, Renal Impairment
Interventions
pudexacianinium chloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Anniston, Alabama • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jul 22, 2026, 1:48 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Working to Increase Stability Through Exercise

NCT02714257
View directory record Official record
Conditions
Fractures, Bone, Serious Fall-related Injuries
Interventions
Enhanced Usual Care plus Exercise Coaching
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years and older
Enrollment
1,139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Recruiting Not applicable Interventional

Helping Adults With Obsessive-Compulsive Disorder Succeed at Work

NCT07124780
View directory record Official record
Conditions
Obsessive-Compulsive Disorder (OCD)
Interventions
Individual Placement and Support (IPS), Standard Vocational Services
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

A Sleep Intervention in Type 1 Diabetes

NCT03617770
View directory record Official record
Conditions
Short Sleep Phenotype, Type1diabetes
Interventions
Sleep Opt-In, Healthy Living
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Working Memory in Older Adults

NCT04362696
View directory record Official record
Conditions
Large-scale Physiological Foundations of Memory Decline in Aging Humans
Interventions
High definition transcranial electrical current stimulation
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 80 Years
Enrollment
964 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 22, 2026, 1:48 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

NCT07625215
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
BAY 3670549, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

NCT04626635
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
REGN7075, Cemiplimab, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685
View directory record Official record
Conditions
Alport Syndrome
Interventions
BAY 3401016, Placebo
Biological · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RHBS Brain and Balance Study of Older Adults

NCT04796870
View directory record Official record
Conditions
Cognitive Performance, Balance
Interventions
Online Brain and Balance Training Program
Other
Lead sponsor
George Mason University
Other
Eligibility
55 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Jul 22, 2026, 1:48 AM EDT